Aim of the study: To improve the fluid status in chronic HD patients (measured as OH (overhydration) or TAFO (time averaged fluid overload)) based on BCM measurements. Up to now, the BCM was occasionally applied in both locations of the study centre.

Prescription of post-dialytic weight target: On a weekly base, the patients are pre-dialytically measured by BCM (body composition monitor).

The time average fluid overload (TAFO) determines the target range. TAFO is defined as the mean value of pre- and post-dialytic overhydration (TAFO = (OHpre+OHpost)/2). The target range is set asymmetrically around a TAFO of 0.8, from -1.0 L to +0.5, i.e. the TAFO target range will be from -0.2 L to 1.3 L.

Treatment thrice weekly with HD or on-line HDF for at least 6 months prior to inclusion

Ability to understand the nature and requirements of the study

Age: at least 18 years

Signed informed consent.

Exclusion Criteria:

Interventional clinical study during the preceding 30 days or previous participation in the same study

Acute or chronic infection (HIV, Hepatitis B or C, ...)

Severe disease (malignant tumour, tuberculosis ...)

Usually single needle HD

Problems with shunt or high recirculation,

Severe intra-dialytic blood pressure instability in the last month

Instable angina pectoris

Major amputation at arm or leg, or a pacemaker.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01492634